Genetically modified human placenta-derived mesenchymal stem cells with FGF-2 and PDGF-BB enhance neovascularization in a model of hindlimb ischemia
Ischemic diseases represent a challenging worldwide health burden. The current study investigated the therapeutic potential of genetically modified human placenta-derived mesenchymal stem cells (hPDMSCs) with basic fibroblast growth factor (FGF2) and platelet-derived growth factor-BB (PDGF-BB) genes...
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Journal Article |
| Published: |
Spandidos Publications
2015
|
| Online Access: | http://hdl.handle.net/20.500.11937/55943 |
| _version_ | 1848759746116452352 |
|---|---|
| author | Yin, T. He, S. Su, Chao Chen, X. Zhang, D. Wan, Y. Ye, T. Shen, G. Wang, Y. Shi, H. Yang, L. Wei, Y. |
| author_facet | Yin, T. He, S. Su, Chao Chen, X. Zhang, D. Wan, Y. Ye, T. Shen, G. Wang, Y. Shi, H. Yang, L. Wei, Y. |
| author_sort | Yin, T. |
| building | Curtin Institutional Repository |
| collection | Online Access |
| description | Ischemic diseases represent a challenging worldwide health burden. The current study investigated the therapeutic potential of genetically modified human placenta-derived mesenchymal stem cells (hPDMSCs) with basic fibroblast growth factor (FGF2) and platelet-derived growth factor-BB (PDGF-BB) genes in hindlimb ischemia. Mesenchymal stem cells obtained from human term placenta were transfected ex vivo with adenoviral bicistronic vectors carrying the FGF2 and PDGF-BB genes (Ad-F-P). Unilateral hindlimb ischemia was surgically induced by excision of the right femoral artery in New Zealand White rabbits. Ad-F-P genetically modified hPDMSCs, Ad-null (control vector)-modified hPDMSCs, unmodified hPDMSCs or media were intramuscularly implanted into the ischemic limbs 7 days subsequent to the induction of ischemia. Four weeks after cell therapy, angiographic analysis revealed significantly increased collateral vessel formation in the Ad-F-P-hPDMSC group compared with the control group. Histological examination revealed markedly increased capillary and arteriole density in the Ad-F-P-hPDMSC group. The xenografted hPDMSCs survived in the ischemic tissue for at least 4 weeks subsequent to cell therapy. The current study demonstrated that the combination of hPDMSC therapy with FGF2 and PDGF-BB gene therapy effectively induced collateral vessel formation and angiogenesis, suggesting a novel strategy for therapeutic angiogenesis. |
| first_indexed | 2025-11-14T10:04:47Z |
| format | Journal Article |
| id | curtin-20.500.11937-55943 |
| institution | Curtin University Malaysia |
| institution_category | Local University |
| last_indexed | 2025-11-14T10:04:47Z |
| publishDate | 2015 |
| publisher | Spandidos Publications |
| recordtype | eprints |
| repository_type | Digital Repository |
| spelling | curtin-20.500.11937-559432025-04-28T02:54:03Z Genetically modified human placenta-derived mesenchymal stem cells with FGF-2 and PDGF-BB enhance neovascularization in a model of hindlimb ischemia Yin, T. He, S. Su, Chao Chen, X. Zhang, D. Wan, Y. Ye, T. Shen, G. Wang, Y. Shi, H. Yang, L. Wei, Y. Ischemic diseases represent a challenging worldwide health burden. The current study investigated the therapeutic potential of genetically modified human placenta-derived mesenchymal stem cells (hPDMSCs) with basic fibroblast growth factor (FGF2) and platelet-derived growth factor-BB (PDGF-BB) genes in hindlimb ischemia. Mesenchymal stem cells obtained from human term placenta were transfected ex vivo with adenoviral bicistronic vectors carrying the FGF2 and PDGF-BB genes (Ad-F-P). Unilateral hindlimb ischemia was surgically induced by excision of the right femoral artery in New Zealand White rabbits. Ad-F-P genetically modified hPDMSCs, Ad-null (control vector)-modified hPDMSCs, unmodified hPDMSCs or media were intramuscularly implanted into the ischemic limbs 7 days subsequent to the induction of ischemia. Four weeks after cell therapy, angiographic analysis revealed significantly increased collateral vessel formation in the Ad-F-P-hPDMSC group compared with the control group. Histological examination revealed markedly increased capillary and arteriole density in the Ad-F-P-hPDMSC group. The xenografted hPDMSCs survived in the ischemic tissue for at least 4 weeks subsequent to cell therapy. The current study demonstrated that the combination of hPDMSC therapy with FGF2 and PDGF-BB gene therapy effectively induced collateral vessel formation and angiogenesis, suggesting a novel strategy for therapeutic angiogenesis. 2015 Journal Article http://hdl.handle.net/20.500.11937/55943 10.3892/mmr.2015.4089 http://creativecommons.org/licenses/by-nc-nd/4.0/ Spandidos Publications fulltext |
| spellingShingle | Yin, T. He, S. Su, Chao Chen, X. Zhang, D. Wan, Y. Ye, T. Shen, G. Wang, Y. Shi, H. Yang, L. Wei, Y. Genetically modified human placenta-derived mesenchymal stem cells with FGF-2 and PDGF-BB enhance neovascularization in a model of hindlimb ischemia |
| title | Genetically modified human placenta-derived mesenchymal stem cells with FGF-2 and PDGF-BB enhance neovascularization in a model of hindlimb ischemia |
| title_full | Genetically modified human placenta-derived mesenchymal stem cells with FGF-2 and PDGF-BB enhance neovascularization in a model of hindlimb ischemia |
| title_fullStr | Genetically modified human placenta-derived mesenchymal stem cells with FGF-2 and PDGF-BB enhance neovascularization in a model of hindlimb ischemia |
| title_full_unstemmed | Genetically modified human placenta-derived mesenchymal stem cells with FGF-2 and PDGF-BB enhance neovascularization in a model of hindlimb ischemia |
| title_short | Genetically modified human placenta-derived mesenchymal stem cells with FGF-2 and PDGF-BB enhance neovascularization in a model of hindlimb ischemia |
| title_sort | genetically modified human placenta-derived mesenchymal stem cells with fgf-2 and pdgf-bb enhance neovascularization in a model of hindlimb ischemia |
| url | http://hdl.handle.net/20.500.11937/55943 |